GGrantIndex
Sort

166,118 grants matching stem cells

Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation

$728,085
Heiddis Valdimarsdottir · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA

Interrogation of the oxidative-stress-induced leukemia program in vivo using metabolic imaging

$728,079
Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Integrins and Ocular Angiogenesis

$728,038
Martin Friedlander · Scripps Research Institute, The · R01 · FY2015 · EY

National Surveillance for Emerging Adenovirus Infections

$728,003
University Of Iowa · R01 · FY2005 · AI

Wnt signaling in hematopoietic development

$728,003
David Traver · University Of California, San Diego · R01 · FY2022 · HL

Genetic underpinnings of craniofacial disorders explored with spatial sequencing

$727,962
Hannele Ruohola-Baker · University Of Washington · R01 · FY2025 · DE

Molecular basis of action and pathogenesis of Clostridium difficile toxin B

$727,954
Min Dong · Boston Children'S Hospital · R01 · FY2019 · AI

Genetic underpinnings of craniofacial disorders explored with spatial sequencing

$727,936
Hannele Ruohola-Baker · University Of Washington · R01 · FY2023 · DE

The 3D-Structures of the Pre-Pro-B and Pro-B Cell Genomes

$727,884
Cornelis Murre · University Of California, San Diego · R01 · FY2019 · AI

Systems biology to predict progression and treatment response in M avium complex pulmonary disease

$727,858
Patricio Escalante · Mayo Clinic Rochester · R01 · FY2025 · AI

Single-cell multi-region dissection of AD-pathogen interactions for HSV-1 and CMV

$727,847
Manolis Kellis · Massachusetts Institute Of Technology · R01 · FY2025 · AG

"Corral and Kill" strategy for HIV eradication using MSC in an SIV model

$727,821
Satya Dandekar · University Of California At Davis · R37 · FY2023 · AI

Functional Analysis of Breast Cancer Susceptibility Genes in Mice

$727,791
Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Genetics and Mechanisms of Mitral Valve Prolapse

$727,787
David J Milan · Massachusetts General Hospital · R01 · FY2016 · HL

Calmodulin-driven Nuclear Trafficking linked to diabetes and insulin signaling

$727,785
John A. Hanover · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK

Extent and Significance of Bacterial DNA Integrations in the Human Cancer Genome

$727,738
Julie Dunning Hotopp · University Of Maryland Baltimore · R01 · FY2020 · CA

Studies in Youths & Young Adults with Obesity & T2DM (07-DK-0115, 10-DK-0163)

$727,715
James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK

Bioengineering of Transplantable Humanized Lungs from iPS Cells

$727,688
Darrell N. Kotton · Boston University Medical Campus · R01 · FY2013 · HL

Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients

$727,648
Gregory Yanik · University Of Michigan At Ann Arbor · R01 · FY2024 · HL

Activation of Proto-Oncogenes by Chromosomal Translocation

$727,613
Peter Aplan · Division Of Clinical Sciences - Nci · ZIA · FY2015 · CA

APOE and microglia-mediated progression in tau pathology in AD

$727,596
Tsuneya Ikezu · Mayo Clinic Jacksonville · R01 · FY2024 · AG

Functional Biointegration of Bioengineered Salivary Tissues in Irradiated Animal Models

$727,581
Mary C Farach-Carson · University Of Texas Hlth Sci Ctr Houston · R01 · FY2022 · DE

Tissue engineering to regenerate functional vocal fold after scarring or tissue loss

$727,539
Jennifer L Long · University Of California Los Angeles · R01 · FY2021 · DC

Validation of a single cell multiplexed in-situ biomarker analysis platform for p

$727,501
Michael Gerdes · General Electric Global Research Ctr · R01 · FY2013 · CA

Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.

$727,496
Rajesh Agarwal · University Of Colorado Denver · U01 · FY2020 · EY